ArticleBioinformatics (Oxford, England)2026
OmicsTransformer: self-supervised masked consistency and uncertainty-aware fusion for robust multi-omics prediction.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
motivationMulti-omics integration can improve cancer diagnosis and prognosis, but current models are limited by extreme dimensionality, redundant raw-feature similarities, missing assays, and incomplete pathway priors. We ask whether biologically meaningful patient manifolds can be learned directly from high-dimensional multi-omics data without heuristic graph construction or fixed knowledge-base constraints.
resultsWe present OmicsTransformer, an end-to-end framework that projects each omics modality into latent patches, enforces masked semantic consistency through an Exponential Cosine Consistency Loss, models global patch dependencies with a Transformer encoder, and fuses modalities by sample-specific uncertainty. Across eight diagnostic and prognostic cohorts, OmicsTransformer achieved strong performance, including 89.4% accuracy for TCGA-BRCA subtyping and 90.6% area under the receiver operating characteristic curve (AUC) for TCGA-LGG grading. It improved recurrence prediction over the pathway-restricted DeepKEGG baseline by approximately 21.5 percentage points in accuracy (ACC) on TCGA-LIHC and 11.1 percentage points in ACC on TCGA-BLCA. Variance-weighted attribution with ensemble stability selection recovered reproducible cross-modal biomarker cores and non-canonical progression drivers. AVAILABILITY AND IMPLEMENTATION: Source code and datasets are freely available at https://github.com/FFJXX/OmicTransformer and https://doi.org/10.6084/m9.figshare.31523905. OmicsTransformer is implemented in PyTorch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.